Sarilumab单药与Sarilumab联合甲氨蝶呤治疗类风湿关节炎的比较
该事后分析比较了Sarilumab单药(MONARCH研究)与Sarilumab联合甲氨蝶呤(MOBILITY研究)治疗类风湿关节炎患者第24周的疗效。经过对基线差异的校正后,两组在CDAI、DAS28-CRP、CRP、血红蛋白、疼痛VAS和FACIT-疲劳等所有评估指标的最小二乘均值变化相似,置信区间重叠。结论认为Sarilumab单药疗效与联合甲氨蝶呤相当。
要点
- Sarilumab单药与联合甲氨蝶呤在第24周的疗效指标变化相似。
- 两组间CDAI、DAS28-CRP等评估的最小二乘均值变化置信区间重叠。
- 基线特征存在差异,但经混合效应模型重复测量校正后结果一致。
核心结论
- Sarilumab单药治疗类风湿关节炎的疗效与Sarilumab联合甲氨蝶呤组合治疗相似。
研究设计与样本
- 事后分析比较MONARCH研究(Sarilumab单药,200mg每2周)与MOBILITY研究(Sarilumab联合甲氨蝶呤)第24周数据。
- 纳入184例Sarilumab单药患者和399例Sarilumab联合甲氨蝶呤患者。
主要发现
- 两组在种族、地区、体重指数分组、类风湿因子、抗环瓜氨酸肽抗体、肿胀关节数、CRP、CDAI和口服糖皮质激素使用方面存在差异(P<0.05)。
- 校正差异后,第24周所有评估指标的最小二乘均值变化(95%CI)组间相似且置信区间重叠:CDAI -28.79 vs -26.21;DAS28-CRP -2.95 vs -2.81;CRP -18.31 vs -16.46;Hb 6.59 vs 8.09;疼痛VAS -33.62 vs -31.66;FACIT-疲劳 9.90 vs 10.24。
临床怎么用
- 对于类风湿关节炎患者,Sarilumab单药可作为与联合甲氨蝶呤疗效相当的治療选择。
局限性
- 本研究为事后分析,非随机对照试验,可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs, such as MTX, has demonstrated improvement in clinical outcomes in patients with RA. The primary objective of this post hoc analysis was to compare the efficacy of sarilumab (200 mg every 2 weeks) monotherapy (MONARCH study) with that of sarilumab and MTX combination therapy (MOBILITY study) at week 24. METHODS: The endpoints assessed were mean change from baseline in the Clinical Disease Activity Index (CDAI), 28-joint Disease Activity using CRP (DAS28-CRP), CRP, haemoglobin (Hb), pain visual analogue scale (VAS) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. Least square (LS) mean change from baseline (95% CI) at week 24 for all endpoints was compared between the treatment arms for adjusted comparisons. RESULTS: This analysis included 184 patients on sarilumab monotherapy and 399 patients on sarilumab plus MTX. Differences (P < 0.05) were observed in ethnicity, region, body mass index group, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, swollen joint count, CRP, CDAI and oral glucocorticoid use between these treatment groups. After adjusting for these differences in a mixed-effect model repeated measure, LS mean change from baseline for all assessments was similar between the treatment groups with overlapping CIs: CDAI, -28.79 vs -26.21; DAS28-CRP, -2.95 vs -2.81; CRP, -18.31 vs -16.46; Hb, 6.59 vs 8.09; Pain VAS, -33.62 vs -31.66; FACIT-Fatigue, 9.90 vs 10.24. CONCLUSION: This analysis demonstrated that the efficacy of sarilumab monotherapy was similar to that of sarilumab and MTX combination therapy.
引用
- Burmester GR, Bykerk VP, Buch MH, et al. Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34508594. doi:10.1093/rheumatology/keab676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。